Halozyme Therapeutics, Inc. (FRA:RV7)

Germany · Delayed Price · Currency is EUR

60.96

-1.18 (-1.90%)

At close: Feb 20, 2026

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
United States Revenue	822.98M	690.46M
United States Revenue Growth	19.19%	17.59%
Switzerland Revenue	276.41M	212.39M
Switzerland Revenue Growth	30.14%	42.52%
Belgium Revenue	217.52M	84.01M
Belgium Revenue Growth	158.93%	43.96%
Japan Revenue	46.37M	18.94M
Japan Revenue Growth	144.85%	25.46%
All Other Foreign Countries Revenue (Post-FY2022)	33.33M	9.53M
All Other Foreign Countries Revenue (Post-FY2022) Growth	249.85%	-51.35%
Revenue (Total)	1.40B	1.02B
Revenue (Total) Growth	37.55%	22.44%

Revenue

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
Royalties Revenue	867.84M	570.99M
Royalties Revenue Growth	51.99%	27.49%
Sales of Proprietary Products	194.61M	166.62M
Sales of Proprietary Products Growth	16.80%	27.35%
Sales of Bulk rHuPH20	133.02M	86.33M
Sales of Bulk rHuPH20 Growth	54.08%	-25.21%
Sales of Device Partnered Products	48.81M	50.54M
Sales of Device Partnered Products Growth	-3.41%	-7.40%
Total Net Product Sales	376.44M	303.49M
Total Net Product Sales Growth	24.04%	0.88%
Revenue Under Collaborative Agreements	152.33M	140.84M
Revenue Under Collaborative Agreements Growth	8.15%	74.88%
Revenue (Total)	1.40B	1.02B
Revenue (Total) Growth	37.55%	22.44%

Updated Dec 31, 2025. Data Source: Fiscal.ai.